Minimal clinically important change on the unified Parkinson's disease rating scale
Identifieur interne : 000751 ( Istex/Curation ); précédent : 000750; suivant : 000752Minimal clinically important change on the unified Parkinson's disease rating scale
Auteurs : Anette Schrag [Royaume-Uni] ; Cristina Sampaio [Portugal] ; Nicholas Counsell [Royaume-Uni] ; Werner Poewe [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-08.
English descriptors
- KwdEn :
Abstract
The Unified Parkinson's Disease Rating Scale (UPDRS) is the main outcome measure in clinical trials of Parkinson's disease (PD). The minimal change that represents a clinically meaningful improvement is unknown. The objective of this study was to determine the minimal change on the UPDRS that represents a clinically meaningful improvement in early PD after 6 months of treatment. Data from two independent randomized treatment trials over 6 months involving 603 patients with de novo PD were analyzed to determine the minimal clinically important change (MCIC), referred to the status before treatment, for the UPDRS motor, activities of daily living (ADL), and total scores. An anchor‐based method using ratings on a seven‐point global clinical improvement was used. A change of five points on the UPDRS motor part was found to be the most appropriate cutoff score for all Hoehn and Yahr stages I to III, and a change of eight points for the UDPRS total score. For the UDPRS ADL score, an MCIC of two points for Hoehn and Yahr stages I/I.5 and II and of three points for Hoehn and Yahr stage II.5/III was the most appropriate cutoff score. These data give the first estimate for cutoffs defining clinically important changes in UPDRS ADL and motor scores. Further studies using larger databases from more diverse study populations are encouraged to better define and solidify the MCIC for the UPDRS. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20914
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000751
Links to Exploration step
ISTEX:9A21C7C1629235028808E950CFCF237D12AFB48DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Minimal clinically important change on the unified Parkinson's disease rating scale</title>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation wicri:level="1"><mods:affiliation>Royal Free and University College Medical School, University College London, London, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Free and University College Medical School, University College London, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation>
<country xml:lang="fr">Portugal</country>
<wicri:regionArea>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Counsell, Nicholas" sort="Counsell, Nicholas" uniqKey="Counsell N" first="Nicholas" last="Counsell">Nicholas Counsell</name>
<affiliation wicri:level="1"><mods:affiliation>GlaxoSmithKline, Harlow, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>GlaxoSmithKline, Harlow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Clinic, Innsbruck, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University Clinic, Innsbruck</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:9A21C7C1629235028808E950CFCF237D12AFB48D</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20914</idno>
<idno type="url">https://api.istex.fr/document/9A21C7C1629235028808E950CFCF237D12AFB48D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000751</idno>
<idno type="wicri:Area/Istex/Curation">000751</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Minimal clinically important change on the unified Parkinson's disease rating scale</title>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation wicri:level="1"><mods:affiliation>Royal Free and University College Medical School, University College London, London, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Free and University College Medical School, University College London, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation>
<country xml:lang="fr">Portugal</country>
<wicri:regionArea>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Counsell, Nicholas" sort="Counsell, Nicholas" uniqKey="Counsell N" first="Nicholas" last="Counsell">Nicholas Counsell</name>
<affiliation wicri:level="1"><mods:affiliation>GlaxoSmithKline, Harlow, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>GlaxoSmithKline, Harlow</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Clinic, Innsbruck, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University Clinic, Innsbruck</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-08">2006-08</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="1200">1200</biblScope>
<biblScope unit="page" to="1207">1207</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">9A21C7C1629235028808E950CFCF237D12AFB48D</idno>
<idno type="DOI">10.1002/mds.20914</idno>
<idno type="ArticleID">MDS20914</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term>
<term>UPDRS</term>
<term>Unified Parkinson's Disease Rating Scale</term>
<term>minimal clinically important change</term>
<term>minimal clinically meaningful improvement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The Unified Parkinson's Disease Rating Scale (UPDRS) is the main outcome measure in clinical trials of Parkinson's disease (PD). The minimal change that represents a clinically meaningful improvement is unknown. The objective of this study was to determine the minimal change on the UPDRS that represents a clinically meaningful improvement in early PD after 6 months of treatment. Data from two independent randomized treatment trials over 6 months involving 603 patients with de novo PD were analyzed to determine the minimal clinically important change (MCIC), referred to the status before treatment, for the UPDRS motor, activities of daily living (ADL), and total scores. An anchor‐based method using ratings on a seven‐point global clinical improvement was used. A change of five points on the UPDRS motor part was found to be the most appropriate cutoff score for all Hoehn and Yahr stages I to III, and a change of eight points for the UDPRS total score. For the UDPRS ADL score, an MCIC of two points for Hoehn and Yahr stages I/I.5 and II and of three points for Hoehn and Yahr stage II.5/III was the most appropriate cutoff score. These data give the first estimate for cutoffs defining clinically important changes in UPDRS ADL and motor scores. Further studies using larger databases from more diverse study populations are encouraged to better define and solidify the MCIC for the UPDRS. © 2006 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000751 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000751 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:9A21C7C1629235028808E950CFCF237D12AFB48D |texte= Minimal clinically important change on the unified Parkinson's disease rating scale }}
This area was generated with Dilib version V0.6.23. |